Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 1Neuroblastoma 1Multiple Endocrine Neoplasia 1Carcinoid Tumor 1Adrenal Gland Neoplasms 1

Interventions

Cyclophosphamide 21Isotretinoin 14Etoposide 13Topotecan 12Irinotecan 12dinutuximab 10Temozolomide 10Magnetic Resonance Spectroscopy 10Doxorubicin 10Melphalan 9sargramostim 8Vincristine 8Filgrastim 7Cisplatin 7Specimen Handling 6Granulocyte-Macrophage Colony-Stimulating Factor 6Granulocyte Colony-Stimulating Factor 6Carboplatin 63-Iodobenzylguanidine 6X-Rays 5Phantoms, Imaging 5Busulfan 5Biopsy 5fludarabine 4etoposide phosphate 4aldesleukin 4Thiotepa 4Stem Cell Transplantation 4Radiotherapy 4Nuclear Medicine Department, Hospital 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neuroblastoma × (18F)GTP1 × Clear all
NCT00947167 2017-03-03

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Stanford University

Phase 2 Terminated
4 enrolled 5 charts
CNSEndocrineNET

Adrenal Gland Neoplasms, Carcinoid Tumor, Multiple Endocrine Neoplasia, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡